Molecular characterization of the tumor microenvironment in breast cancer  by Allinen, Minna et al.
A R T I C L E
Molecular characterization of the tumor microenvironment
in breast cancer
Minna Allinen,1,3 Rameen Beroukhim,1,3,10 Li Cai,2,10 Cameron Brennan,1,10 Jaana Lahti-Domenici,1
Haiyan Huang,2,6,11 Dale Porter,1,3 Min Hu,1,3 Lynda Chin,1,4 Andrea Richardson,5,7 Stuart Schnitt,5,8
William R. Sellers,1,3,9 and Kornelia Polyak1,3
1Department of Medical Oncology
2 Department of Research Computing
Dana-Farber Cancer Institute, Boston, Massachusetts 02115
3 Department of Medicine
4 Deparment of Dermatology
5 Department of Pathology
Harvard Medical School, Boston, Massachusetts 02115
6 Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115
7 Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts 02115
8 Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115
9 Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142
10These authors contributed equally to this work.
11Present address: Department of Statistics, University of California, Berkeley, Berkeley, California 94720.
*Correspondence: kornelia_polyak@dfci.harvard.edu
Summary
Here we describe the comprehensive gene expression profiles of each cell type composing normal breast tissue and in
situ and invasive breast carcinomas using serial analysis of gene expression. Based on these data, we determined that
extensive gene expression changes occur in all cell types during cancer progression and that a significant fraction of
altered genes encode secreted proteins and receptors. Despite the dramatic gene expression changes in all cell types,
genetic alterations were detected only in cancer epithelial cells. The CXCL14 and CXCL12 chemokines overexpressed in
tumor myoepithelial cells and myofibroblasts, respectively, bind to receptors on epithelial cells and enhance their prolifera-
tion, migration, and invasion. Thus, chemokines may play a role in breast tumorigenesis by acting as paracrine factors.
Introduction culescu et al., 1995). Using these approaches, the molecular-
based classification of breast cancer has become a reality, and
molecular signatures correlating with metastatic behavior andBreast cancer is the most commonly identified and one of the
clinical outcome have been identified (Ramaswamy et al., 2003;deadliest neoplasms in women in Western countries. The recent
Sorlie et al., 2001; van ’t Veer et al., 2002; van de Vijver et al.,trend toward improvement in breast cancer mortality rate is
2002). However, since most of these analyses were performedlargely due to increased diagnosis of early stage disease, while
using bulk tissue samples that are composed of multiple cellour therapeutic options for advanced stage breast carcinomas
types or purified tumor epithelial cells, the specific contributionare still fairly limited. Thus, there is a need to better understand
the molecular basis of breast cancer initiation and progression of epithelial and stromal cells to these tumor classifiers and
prognostic signatures is unknown. Similarly, in the past decadesand to use this knowledge for the design of targeted, molecular-
based therapies. In the past few years, newly developed tech- the major focus of cancer research has been the transformed
tumor cell itself, while the role of the cellular microenvironmentnologies such as microarrays and SAGE (serial analysis of gene
expression) have enabled us to analyze molecular differences in tumorigenesis has not been widely explored. Early studies
demonstrated the ability of stromal tissues to regulate thebetween normal and cancer cells at a genome-wide level in
comprehensive and unbiased ways (Schena et al., 1995; Vel- growth and differentiation state of breast cancer cells (DeCosse
S I G N I F I C A N C E
Despite compelling cell biological studies and histopathological observations incriminating myoepithelial and stromal cells in tumori-
genesis, our knowledge of the genes that mediate changes in the tumor microenvironment and interactions among various cell
types in breast cancer and their role in tumorigenesis is limited. Similarly, the occurrence and role of genetic changes in stromal
cells are undefined. Here, we describe a comprehensive molecular characterization of each cell type composing normal breast tissue
and in situ and invasive breast carcinomas. We identified several genes as potential mediators of epithelial-stromal/myoepithelial cell
interactions, including the CXCL12 and CXCL14 chemokines. These data should therefore provide a valuable resource for future
basic and clinical studies addressing the role of epithelial-stromal/myoepithelial cell interactions in breast cancer.
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et al., 1973, 1975), and several recent in vivo and in vitro studies the myofibroblasts using CD10 beads. Several recent studies
have demonstrated that the growth, differentiation, invasive be- reported that some morphologically distinct myoepithelial cells
havior, and polarity of normal mammary epithelial cells and lack CD10 and other myoepithelial cell markers (Zhang et al.,
breast carcinomas are influenced by surrounding stromal cells 2003). Thus, due to the use of CD10 beads for the isolation of
including fibroblasts, myofibroblasts, leukocytes, and myoepi- myoepithelial cells, a subset of myoepithelial cells may have
thelial cells (Bissell and Radisky, 2001; Radisky et al., 2001; been excluded from our study. We were not able to identify an
Tlsty, 2001). In addition, certain histopathological features of antibody that would specifically recognize fibroblasts and allow
breast tumors, including lymphocytic infiltration, fibrosis, and their purification; thus, we used the unbound fraction following
angio- and lymphangiogenesis, have proven prognostic signifi- the removal of all other cell types as a fibroblast-enriched “stro-
cance. Despite these convincing data implicating a role for the mal” fraction. A detailed description of the purification method is
tumor microenvironment in breast tumorigenesis, our under- described in the Supplemental Data (http://www.cancercell.org/
standing of the genes mediating cellular interactions and para- cgi/content/full/6/1/17/DC1). Since this protocol includes se-
crine regulatory circuits among various cell types in normal and quential enzymatic digestion of the tissue, the possibility that the
cancerous breast tissue and their role in breast tumorigenesis expression of some genes could be altered due to the procedure
is limited. cannot be excluded. However, since we were able to verify the
In the past few years, the role of the cellular microenviron- SAGE data by alternative methods using unprocessed tissue
ment in tumorigenesis has become an intense area of research. (Figure 3), these changes (if any) are likely to be minimal. The
This is in part due to studies demonstrating that genetic abnor- success of the purification method and the purity of each cell
malities, such as loss of heterozygosity (LOH), occur not only fraction were confirmed by performing RT-PCR on a small frac-
in cancer cells, but in stromal cells as well (Kurose et al., 2001, tion of the isolated cells using cell type-specific genes (Figure
2002; Lakhani et al., 1998; Moinfar et al., 2000). However, no 1B). The remaining portion of the cells (10,000–100,000 cells,
genes presumably targeted by these genetic events in stromal depending on the sample) was used for the generation of micro-
cells have been identified; thus, their role in breast tumorigenesis SAGE libraries following previously described protocols (Porter
is still unknown. et al., 2001, 2003a) and for the isolation of genomic DNA to be
As a consequence of studies focusing almost exclusively on used for array comparative genomic hybridization (aCGH) and
cancer cells, nearly all of the currently used cancer therapeutic single nucleotide polymorphism (SNP) array studies. We have
agents target the cancer cells that, due to their inherent genomic generated SAGE libraries from epithelial and myoepithelial cells
instability, frequently acquire therapeutic resistance (Rajagopa-
(myofibroblasts from invasive tumors), infiltrating lymphocytes,
lan et al., 2003). In part due to frequent therapeutic failures
endothelial cells, and fibroblasts (stroma) from one normal
during the course of treatment of advanced stage tumors, in-
breast reduction tissue, two different DCIS, and three invasivecreasing emphasis has been placed on targeting various stromal
breast tumors. Not all libraries were generated from all casescells, particularly endothelial cells, via therapeutic interventions.
due to our inability to obtain sufficient amounts of purified cells.Since these cells are thought to be normal and genetically stable,
In addition, we also included a fibroadenoma and a phyllodesthey are less likely to develop acquired resistance to cancer
tumor in our SAGE analyses. Fibroadenomas are the most com-therapy. Thus, isolating and characterizing each cell type (epi-
mon benign breast tumors that are not considered to progressthelial, myoepithelial, and various stromal cells) comprising non-
to malignancy despite genetic changes detected in the stromalmalignant and cancerous breast tissue would not only help us
(but not epithelial) cells (Amiel et al., 2003). Phyllodes tumors,to understand the role these cells play in breast tumorigenesis,
on the other hand, are rare fibroepithelial tumors that are usuallybut would likely give us new molecular targets for cancer inter-
benign but can recur and progress to malignant sarcomas. Ini-vention and treatment.
tially, phyllodes tumors were considered stromal neoplasms, but
recent molecular studies demonstrating (frequently discordant)Results
genetic alterations in both epithelial and stromal cells suggests
that phyllodes tumors may represent a true clonal co-evolutionPurification of all cell types present in breast tissue
of malignant epithelial and stromal cells (Sawyer et al., 2000,To determine the molecular profile of each cell type that, to-
2002). A detailed description of the tissue samples and thegether, compose the breast tissue and to identify autocrine
SAGE libraries is included in the Supplemental Data online.and paracrine interactions that may play a role in breast tumor
Analysis of the SAGE data confirmed that the cell purificationprogression, we developed a purification procedure that allows
procedure worked well, since several genes known to be spe-the isolation of pure cell populations from normal breast tissue
cific for a particular cell type were present in the appropriateand from in situ (ductal carcinoma in situ, DCIS) and invasive
SAGE libraries. For example, cytokeratins 8 and 19, E-cadherin,breast carcinomas (Figure 1A). We utilized cell type-specific cell
HIN-1, and CD24 were highly specific for epithelial cells (HIN-1surface markers and magnetic beads for the rapid sequential
only for normal epithelial cells); myofibroblast and myoepithelialisolation of the various cell types. We used the BerEP4 antigen
cells demonstrated high levels of smooth muscle actin, variousrestricted to epithelial cells, the CD45 panleukocyte marker,
extracellular matrix proteins including collagens, and matrixand the P1H12 antibody that specifically recognizes endothelial
metalloproteinases; and leukocyte libraries had the highest lev-cells. The CD10 antigen is present in myoepithelial cells and
els of several chemokines and lysozyme (Table 1 and Supple-myofibroblasts, but also in some leukocytes. Thus, to minimize
mental Table S1). In general, SAGE libraries prepared from thethe crosscontamination of these different cell types, in the case
same cell type purified from different tissue samples were highlyof normal (N-MYOEP-1) and DCIS breast tissue, myoepithelial
similar to each other, although there were differences as well,cells were isolated from organoids (breast ducts), while in inva-
sive tumors we first removed the leukocytes prior to capturing likely due to variability among patients and also slight variability
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Figure 1. Isolation and characterization of each cell type comprising normal and cancerous breast tissue
A: Schematic outline of tissue fractionation and sequential purification of the various cell types from normal breast tissue and in situ and invasive breast
carcinomas. The procedure is described in detail in the online Supplemental Data.
B: RT-PCR analysis of each cell fraction isolated from DCIS-7 using known cell type-specific genes to confirm the purity of the cells and integrity of the
mRNA. MME (CD10) is highly specifically expressed in CD10 myoepithelial cells and myofibroblasts, PTPRC (CD45) in leukocytes, and CDH5 (endothelial
cadherin) in endothelial cells. Although ERBB2 is not an absolutely epithelial cell-specific gene, its abundance is highest in luminal epithelial cells. PCR was
performed at 25, 30, and 35 cycles. Genes expressed at equal levels in all cell types; -actin (ACTB) and ribosomal protein L19 (RPL19) were used as
controls.
C: Heat map depicting the relatedness of the different SAGE libraries based on 417 cell type-specific tags. Color scheme: blue, downregulated (low tag
counts); green, mean tag counts; yellow, upregulated (high tag counts). The names of the SAGE libraries prepared from epithelial cells are in red,
myoepithelial cells and myofibroblasts in green, stroma in yellow, leukocytes in blue, endothelial cells in pink, and fibroadenoma and phyllodes tumor
(stroma fraction) in purple. A detailed description of the SAGE libraries and tissue samples is included in Supplemental Data.
D: Heat map depicting the relatedness of the different SAGE libraries based on the 63 most highly cell type-specific tags. Color scheme and SAGE library
names are described as above.
in the purification procedure itself (see Supplemental Data for (Tables 1 and 2 and Supplemental Tables S1–S15). Genes were
defined as specific for a particular cell type if the average tagmore details).
number in all the SAGE libraries generated from the selected
cell type was statistically significantly (p  0.02) different fromComprehensive gene expression profile
of each cell type all other cell types. For the purpose of these comparisons, we
considered myoepithelial cells and myofibroblasts as one groupBased on statistical methods developed for the analysis of
SAGE data (see Experimental Procedures, Supplemental Data; due to their high degree of similarity, although there are genes
that are specific for myoepithelial cells and myofibroblasts, re-Cai et al., 2004), we identified genes that are specifically ex-
pressed in a particular cell type and tumor progression stage spectively (Ronnov-Jessen et al., 1996). Using these criteria,
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Table 1. List of 63 most highly cell type-specific tags and corresponding genes
SAGE tag numbers in the various libraries are indicated. Coloring reflects tag abundance in the different cell types.
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Table 2. List of genes encoding secreted proteins and receptors overexpressed in DCIS myoepithelial cells compared to normal myoepithelium
SAGE tag numbers reflect tag numbers normalized to the SAGE library with the highest tag number. Ratio was calculated as a ratio of the average tag
numbers in the two DCIS myoepithelial libraries divided by the tag numbers in the normal myoepithelial library. Genes highlighted in red were selected for
follow-up studies.
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we identified 357 tags that differentiate epithelial cells from be able to suppress breast cancer cell growth, invasion, and
angiogenesis (Deugnier et al., 2002; Sternlicht and Barsky,other cell types, 572 tags specifying myoepithelial cells and
myofibroblasts, 502 tags discriminating leukocytes, 604 tags 1997). The main distinguishing feature of in situ and invasive
carcinomas, which is also used as a diagnostic criteria, is thatselecting stroma, and 124 tags discerning endothelial cells from
other cells. To further define SAGE tags specific for each cell in DCIS, the cancer epithelial cells are separated from the stroma
by a nearly continuous layer of myoepithelial cells and basementtype, within each group of tags we selected the ones that were
not only statistically significantly different, but also more abun- membrane, while in invasive and metastatic tumors, cancer cells
are admixed with stroma. Due to our SAGE and previouslydant in the specific cell type. This led to the identification of 70
tags that were most abundant in epithelial cells, 117 tags present published data suggesting a role for these cells in breast tumor
progression, we focused our follow-up studies on myoepithelialat highest levels in myoepithelial cells and myofibroblasts, 70
tags highly expressed in leukocytes, and 117 stroma- and 78 cells with special emphasis on secreted proteins and receptors
abnormally expressed in these cells. Several proteases (cathep-endothelium-specific tags (Supplemental Tables S3, S5, S7,
S9, and S11). Several of these genes have previously been sins F, K, and L, MMP2, and PRSS11), protease inhibitors
(thrombospondin 2, SERPING1, cystatin C, and TIMP3), anddescribed as being specific for a particular cell type, such as
keratins 8 and 19 for epithelial cells, keratins 14 and 17 for many different collagens were highly upregulated in DCIS myo-
epithelial cells, suggesting a role for these cells in extracellularmyoepithelial cells, and chemokines and chemokine receptors
for leukocytes (Page et al., 1999), but the cell type-specific matrix remodeling (Table 2).
expression of the majority of the genes has not been docu-
mented. The majority of the transcripts corresponding to these Analysis of the genotype of epithelial, myoepithelial,
and stromal cellscell type-specific SAGE tags encode known genes, but a sig-
nificant fraction are uncharacterized ESTs or currently have no To determine if the dramatic gene expression changes observed
in tumor myoepithelial and stromal cell types could be due tocDNA match (10% of the tags on average belong to each of
these last two groups). The only exceptions were tags most underlying genetic alterations, we first performed aCGH analysis
of epithelial and myoepithelial cells and of myofibroblasts fromabundant in stroma, since in this group 25/117 tags (21%) had
no database match, suggesting that they correspond to pre- two DCIS (DCIS-6 and -7) and one invasive breast carcinoma
(IDC7) used for SAGE. As expected, we detected numerousviously unidentified transcripts.
Next, using the SAGE tags most abundant in (417 tags) or chromosomal gains and losses in the tumor epithelial cells,
while no changes were detected in myoepithelial cells and myo-most highly specific for (63 tags) each of the five cell types, we
performed clustering analysis of all 27 SAGE libraries using a fibroblasts (Figures 2A and 2B). Similarly, no genetic changes
were detected in epithelial and myoepithelial cells isolated fromnew Poisson model-based K-means algorithm (PK algorithm,
Supplemental Data; Cai et al., 2004) to delineate similarities and normal tissue adjacent to the tumors (Figure 2A). These data
suggest that although nonepithelial cells in breast tumors aredifferences among the samples (Figures 1C and 1D). In addition,
we also performed clustering analysis of the SAGE libraries phenotypically distinct from their normal counterparts, genetic
changes detectable by aCGH appear to be limited to cancerusing each of the cell type-specific gene sets (Supplemental
Figures S1 and S2). The PK clustering method orders the sam- epithelial cells. However, since array CGH is thought to be more
sensitive for the detection of copy number gains than lossesples according to their relatedness. For example, using the 63
most highly cell type-specific SAGE tags, we obtained a division and previous studies demonstrated LOH in stromal cells, we
applied another technology, SNP arrays, for the analysis ofof the 27 SAGE libraries according to cell types, and within each
cell type subgroup, the DCIS samples were located between isolated epithelial and stromal cells from a set of breast tumors.
As expected, cancer epithelial cells from all but one invasivenormal breast tissue and invasive breast cancer SAGE libraries
(Figure 1D). This result indicates that not only tumor epithelial breast tumor demonstrated numerous LOH on nearly all chro-
mosomes, while myofibroblasts and other stromal cells fromcells, but also other cell types in the tumor, are different from
their corresponding normal counterparts. Since these differ- the same tumors appeared to be mostly normal (Figure 2C
and Supplemental Figure S3). Clustering analysis based on theences are already pronounced at a pre-invasive (DCIS) tumor
stage, they suggest a role for stromal changes not only in tumor inferred LOH data clearly divided the samples into two major
groups, the tumor epithelial and stromal cells from differentinvasion and metastasis, but also in the earlier steps of breast
tumorigenesis. cases demonstrating more similarity to each other than to their
corresponding other cell type (Figure 2C). The only exceptionBased on our SAGE data, we found that the most consistent
and dramatic gene expression changes occur in myoepithelial was epithelial cells from IDC10 (a low-grade estrogen receptor-
positive tumor) that did not appear to have major geneticcells. More than 300 genes were differentially expressed at p 
0.002 in both DCIS myoepithelial libraries, and interestingly, a changes (the purity of the tumor epithelial cells was confirmed
by RT-PCR, data not shown), while in the phyllodes tumor, thesignificant fraction of these genes (89 out of 245 characterized
genes) encode secreted or cell surface proteins, suggesting stroma had numerous genetic alterations with much fewer LOH
events detected in the epithelial cells. We did not detect signifi-extensive abnormal paracrine interactions between myoepithe-
lial and other cell types (Supplemental Table S5). Myoepithelial cant LOH in the three fibroadenomas analyzed or in the one
LCIS (lobular carcinoma in situ) case. Two nonepithelial samplescells are thought to be derived from bipotential stem cells that
also give rise to luminal epithelial cells, although recently another (I-MYOFIB-8 and I-STR-13) had a few areas where 2–5 adjacent
SNPs exhibited LOH (Figure 1C), but careful examination ofprogenitor has been identified that can differentiate only into
myoepithelial cells (Bocker et al., 2002; Dontu et al., 2003). The these SNPs individually suggested that these LOH calls are
likely due to poor hybridization results. In order to resolve thisfunction of myoepithelial cells and their role in breast cancer are
not well understood, but myoepithelial cells have been shown to issue, we amplified and sequenced eight of these ambiguous
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Figure 2. Genotype analysis of fractionated normal and tumor breast tissue
A: Array CGH analysis of luminal epithelial (red line) and myofibroblasts (green line) cells isolated from IDC-7 invasive breast tumor used for SAGE and from
adjacent normal tissue. Mode centered segmented data, significant gains and losses defined as Log2 signal ratio of greater than or equal to0.13 or0.13,
respectively, are depicted.
B: Array CGH analysis of luminal epithelial (red line) and myoepithelial (green line) cells from DCIS-6 and DCIS-7. Areas with statistically significant gains in
the epithelial cells (chromosome 17 in the case of DCIS-6 and chromosome 20 for DCIS-7) are depicted, indicating that myoepithelial cells do not share
these changes with the epithelial cells. No significant gains and losses were detected in any other areas of the genome in the myoepithelial cells (data
not shown).
C: SNP array analysis of purified epithelial and stromal cells from invasive breast carcinomas, phyllodes tumor, fibroadenomas, and LCIS. Samples are
clustered based on inferred loss of heterozygosity (LOH). All but one tumor epithelial DNA sample are clustered together to the left, while all stromal samples,
regardless of their origin, are clustered together to the right. Inferred loss of heterozygosity (LOH) is indicated in blue, yellow indicates regions retaining
heterozygosity, and white regions are indeterminate (noninformative). The names of DNA samples obtained from epithelial cells are depicted in red,
myofibroblasts in green, stroma in yellow, leukocytes in blue, endothelial cells in pink, fibroadenoma in purple, and LCIS in black. A detailed description of
the samples is included in the online Supplemental Data.
D: Sequence analysis of two ambiguous SNP cells present in I-MYOFIB-8 and in several controls. For all cases, the chromatograms of the sequence reads
and the SNP array calls are indicated. One of the SNPs (rs952018) is on chromosome 13q33.2, while the other one (rs1019215) is on chromosome 11p14.3.
As depicted in the figure in the case of SNP rs952018, the I-MYOFIB-8 sample had both “A” and “G” peaks just like the N-EPI-I7 sample, proving the retention
of both alleles, while the I-LEU-14 sample was homozygous for the “G” allele and the N-for IDC11 (normal DNA corresponding to tumor IDC11) was
homozygous for the “A” allele. Similarly in the case of SNP rs952018, the I-MYOFIB-8 sample had both T and C peaks just like the N-for IDC15 (normal DNA
corresponding to tumor IDC15), while the N-EPI-I7 and I-EPI-15 were both homozygous for the “C” allele.
SNPs from these two stromal samples (I-MYOFIB-8 and I-STR- Evaluation of gene expression
by immunohistochemistry and mRNA13) together with several controls, where the SNP results clearly
depicted heterozygous or homozygous alleles. In all seven in situ hybridization
The generation of the SAGE libraries involved the in vitro purifi-cases in which high-quality sequencing results were obtained,
we found no evidence of LOH in either of these two ambiguous cation of the cells that could potentially alter the in vivo gene
expression patterns, although prior SAGE data from severalstromal samples (Figure 2D).
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laboratories suggest that these changes are likely to be minimal
(Porter et al., 2003a, 2003b; St Croix et al., 2000). However, in
order to further investigate the expression of selected genes at
the cellular level in vivo, we performed immunohistochemical
analyses and mRNA in situ hybridization in a panel of DCIS and
invasive breast tumors (including tumors used for SAGE as well
as additional cases). In addition, the cell type specificity of some
genes was verified by RT-PCR in the samples used for SAGE
(data not shown). Immunohistochemical analysis confirmed that
two genes, IL-1 and CCL3 (MIP1), are highly expressed in
leukocytes infiltrating DCIS, but not normal breast tissue,
whereas the PTPRC (CD45) panleukocyte marker was ex-
pressed in both cases (Figure 3A). Despite the similar number
of total leukocytes in invasive tumors, the frequency of IL-1
and CCL3-positive leukocytes was much lower than in DCIS,
suggesting that in situ and invasive breast carcinomas may be
immunologically dissimilar. mRNA in situ hybridization deter-
mined that in DCIS tumors, the expression of PDGF receptor
-like (PDGFRBL), cathepsin K (CTSK), and CXCL12 was local-
ized to myofibroblasts as determined by smooth muscle actin
(ACTA2) staining, CXCL14 was expressed only in myoepithelial
cells, while TIMP3, cystatin C (CST3), and collagen triple helix
repeat containing 1 (CTHRC1) were expressed in both myoepi-
thelial cells and myofibroblasts. In invasive tumors, all seven
genes were expressed in myofibroblasts. No signal was de-
tected in normal breast tissue nor with the sense probes (Figure
3B, Supplemental Figure S4, and data not shown). Interestingly,
although in DCIS tumors we detected CXCL14 expression only
in myoepithelial cells, in some (4/9) invasive breast carcinomas,
the expression of CXCL14 was restricted to the tumor epithelial
cells (Figures 3B and 4A). Similarly, some breast cancer cell
lines expressed high levels of CXCL12 or CXCL14 in vitro, sug-
gesting that during tumor progression a paracrine factor may
be converted into an autocrine one due to its upregulation in
the tumor epithelial cells (Figure 4B). Interestingly, all CXCL14-
positive invasive ductal carcinomas and even the CXCL14 ex-
pressing breast cancer cell line (UACC812) were obtained from
young, premenopausal patients (average age of onset 39 years),
suggesting a possible association of CXCL14 expression with
hormone levels or clinico-pathologic characteristics of the tu- Figure 3. Validation of SAGE data using immunohistochemistry and mRNA
mors, the analysis of which requires the examination of larger in situ hybridization and Northern blot analysis
tumor sets. A: Immunohistochemical analysis of PTPRC (CD45), IL1, and CCL3 expres-
sion in normal, DCIS, and invasive cancer breast tissue. Black signal indicates
expression of the indicated proteins in leukocytes. Methyl green was usedThe effect of CXCL12 and CXCL14 chemokines
to stain the nuclei to visualize tissue histology. Magnification is 100.on breast cancer cells
B: mRNA in situ hybridization analysis of the indicated genes using antisense
The high level of expression of two chemokines, CXCL12 and ribo-probes in a panel of normal, DCIS, and invasive breast cancer tissue.
CXCL14, in myoepithelial cells and myofibroblasts both in DCIS Red (PDGFRL, CTSK, CTHRC1, TIMP3, CST3, and CXCL12) or black (CXCL14
and IGFBP7) staining indicates the presence of the mRNA depending onand invasive breast carcinomas was particularly interesting due
the hybridization protocol used. Paraffin sections were analyzed for ACTA2to the known function of chemokines as regulators of cell prolif-
(smooth muscle actin) expression by immunohistochemistry to confirm theeration, differentiation, migration, and invasion (Gerard and Rol-
identity of myoepithelial cells and myofibroblasts. Brown staining indicates
lins, 2001; Muller et al., 2001; Rossi and Zlotnik, 2000). To the expression of SMA in myoepithelial cells and myofibroblasts. Magnifica-
determine if CXCL12 and CXCL14 may act as autocrine and/ tion is 100. More detailed images with higher (200) magnification are
included in Supplemental Data (Supplemental Figure S4).or paracrine factors in breast tumors, we investigated which
cell types appear to have receptors for these chemokines in vivo
in primary breast tissue. The signaling receptor for CXCL12
is CXCR4, which is known to be widely expressed in various
(data not shown). The signaling receptor of CXCL14 is unknown,lymphoid as well as a variety of epithelial cells (Gerard and
but cell surface ligand binding experiments have suggested theRollins, 2001). We confirmed the expression of CXCR4 in
presence of a putative CXCL14 receptor on monocytes and Blymphoid and breast epithelial cells using immunohistochemis-
cells, suggesting that its receptor is not likely to be CXCR4try, while SAGE data indicated that its expression is increased
in invasive tumors compared to DCIS and normal breast tissue (Kurth et al., 2001; Sleeman et al., 2000). To determine if a
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Figure 4. CXCL14 expression in primary breast tumors and breast cancer cell lines
A: mRNA in situ hybridization using CXCL14 antisense ribo-probe in multiple DCIS and invasive breast carcinomas including the tumors used for SAGE
(DCIS-7). Black/purple staining indicates the presence of the CXCL14 mRNA, while nuclei were stained with nuclear FastRed to visualize tissue histology.
The names of the tumor samples are indicated above/below of the pictures. In DCIS cases, CXCL14 is expressed only in myoepithelial cells, while in some
invasive breast carcinomas (CT22 and CT25), strong expression is observed in tumor epithelial cells.
B: Northern blot analysis of CXCL12, CXCL14, and CXCR4 expression in the indicated breast cancer cell lines, breast organoids (ORG1–10, uncultured breast
ducts from normal breast tissue), and primary breast tumor CT22. Hybridization with -actin (ACTB) was used as a control for loading. Confirming the mRNA
in situ hybridization data, strong CXCL14 expression is detected in tumor CT22, similarly in SUM-229 and UACC812 breast cancer cell lines.
CXCL14 binding cell surface protein(s) is also present on breast CXCL14 has similar effects, we tested the effect of conditioned
medium containing AP-CXCL14 on the growth of MDA-MB-231cancer cells, we generated an alkaline phosphatase-CXCL14
(AP-CXCL14) fusion protein to be used as a ligand in receptor and MCF10A cells, while its effect on cell migration and invasion
was investigated in MDA-MB-231 cells. Conditioned mediasbinding assays. Conditioned media of AP-CXCL14 or control
AP expressing cells was then used as an affinity reagent to stain of cells transfected with AP alone and CXCL12 were used as
negative and positive controls, respectively. Similar to CXCL12,normal and cancerous mammary tissue sections including the
DCIS tumors used for SAGE. Blue staining indicated the pres- CXCL14 enhanced the proliferation of MDA-MB-231 and
MCF10A cells and the migration and invasion of MDA-MB-231ence of a CXCL14 binding protein in certain leukocytes and
breast epithelial cells (Figure 5A). These results suggest the cells (Figures 5C and 5D, and data not shown). The concentra-
tion of AP-CXCL14 was 2–30 nM in these experiments, whichpresence of a cell surface CXCL14 binding protein(s) in cancer-
ous and normal mammary epithelial cells and are consistent is similar to the concentration required by several chemokines,
including CXCL12, to exert biological effects. The same resultswith a paracrine mechanism of CXCL14 action in the breast.
To test further the binding characteristics of AP-CXCL14, we were obtained in cell migration and invasion assays using
CXCL14-AP (C-terminal AP-tag) and CXCL14-HA (C-terminalperformed in vitro ligand binding assays using various cell lines.
Low-level AP-CXCL14 binding was detected in all cell lines HA-tag) fusion proteins (Figure 5D and data not shown); thus,
the observed effects are not likely to be due to the position ortested, including MDA-MB-231 and MDA-MB-435 breast can-
cer and MCF10A immortalized mammary epithelial cells (data identity of the epitope tag. Preliminary results using recombinant
CXCL14 protein and CXCL14 expressing adenovirus demon-not shown). To further characterize the AP-CXCL14-putative
CXCL14 receptor interaction, we performed more detailed bind- strated possible induction of calcium flux in MDA-MB-231 and
activation of AKT in MCF10A cells, respectively (data noting assays in MDA-MB-231 breast cancer cells. Scatchard plot
analysis showed two binding slopes in MDA-MB-231 cells indi- shown), further suggesting that mammary epithelial cells have
a functional CXCL14 receptor.cating the presence of high-affinity (Kd  6.1  108 M) and
low-affinity (Kd  56.7  108 M) binding sites (Figure 5B). To determine if paracrine factors, including CXCL14, se-
creted by DCIS myoepithelial cells may influence the prolifera-In previous studies, CXCL12 was demonstrated to enhance
breast cancer cell growth, migration, and invasion (Hall and tion of tumor epithelial cells in vivo, we analyzed the expression
of Ki67, a marker of cell proliferation, in the two DCIS samplesKorach, 2003; Muller et al., 2001). In order to determine if
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Figure 5. Analysis of CXCL14 ligand binding characteristics and function
A: Identification of a putative CXCL14 receptor in breast epithelial cells using an AP (alkaline phosphatase)-CXCL14 fusion protein as ligand. Blue staining
reflecting AP activity indicates binding of AP-CXCL14 to breast epithelial cells and some stromal leukocytes, while no staining is detected with the AP alone
negative control. All these tumor samples were also analyzed for the expression of CXCL14 by mRNA in situ hybridization (Figures 3B and 4A) and were
expressing CXCL14 in tumor epithelial cells (CT22 and CT25) and DCIS myoepithelial cells (T18 and T25). Images were taken with 10 and 20 objectives
(100 and 200 magnification).
B: Scatchard transformation of AP-CXCL14 binding assays in MDA-MB-231 cells. Red and black colored lines indicate high (Kd  6.1  108 M) and low
(Kd  56.7  108 M) -affinity binding slopes, respectively.
C: The effect of CXCL12 and AP-CXCL14 on the growth of MDA-MB-231 breast cancer and MCF10A immortalized breast epithelial cells (red lines) compared
to AP and control media (black lines). Representative result of experiments performed in triplicate.
D: The effect of CXCL14 and 10% fetal bovine serum (FBS) on the migration and invasion of MDA-MB-231 breast cancer cells. The number of cells that
crossed the uncoated (migration) or Matrigel-coated membranes (invasion) is indicated on the y axis. Representative result of experiments performed in
triplicate.
E: Immunohistochemical analysis of Ki67 expression in DCIS-6 and DCIS-7 samples to identify proliferating cells. Images were taken with 10 and 20
objectives (100 and 200 magnification). Ki67 is expressed in all phases of the cell cycle except in noncycling (G0) cells. Tumor epithelial cells adjacent
to the myoepithelial cell layer are more frequently positive than their more centrally located counterparts.
used for SAGE (Figure 5E). In both cases, epithelial cells adja- Discussion
cent to the myoepithelial cell layer were more frequently positive
for Ki67 than tumor epithelial cells in other parts of the ducts. Epithelial-mesenchymal interactions are known to be important
for the normal development of the mammary gland and to playThis result suggests that tumor epithelial cells may receive para-
crine signals from adjacent myoepithelial cells that enhance a role in breast tumorigenesis (Bissell et al., 2002; Coussens
and Werb, 2002; Kenny and Bissell, 2003; Radisky et al., 2001;their proliferation, although other reasons for this intraductal
location-dependent proliferation difference cannot be excluded. Shekhar et al., 2003; Tlsty, 2001; Tlsty and Hein, 2001; Wiseman
and Werb, 2002). Early studies demonstrated that the normalCorrelating with this, a recent study described that the gene
expression profile of tumor epithelial cells located at the periph- mammary microenvironment is capable of “reverting” the neo-
plastic phenotype of breast cancer cells by inducing cellularery and the center of DCIS ducts is significantly different (Zhu
et al., 2003). differentiation (DeCosse et al., 1973, 1975), suggesting that
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cancer cells can thrive only in a distorted environment or have isolated, uncultured myoepithelial cells from normal breast tis-
sue also demonstrated the high expression of laminin, tenascin,to become independent of extracellular signals. The contribution
of genetic host factors to tumor initiation, progression, and angi- thrombospondin, and PAI-1 binding protein. However, the ex-
pression of these genes was downregulated in DCIS myoepithe-ogenesis also support a role for nonepithelial cells in carcinogen-
esis (Hunter, 2004; Rohan et al., 2000). This was dramatically lial cells similar to that of cytokeratins 7, 14, and 17, oxytocin
receptor, and tropomyosin, suggesting that DCIS myoepithelialillustrated by the finding that inactivation of TGF- type II recep-
tor in stromal fibroblasts led to prostate and gastric epithelial cells are phenotypically altered and less differentiated than nor-
mal myoepithelial cells. Keeping with this, several recent studiesneoplasia (Bhowmick et al., 2004). Similarly, a recent finding
demonstrating that mammary tumors only formed in cleared described a lack of commonly used myoepithelial markers (in-
cluding CD10 and SMA) in a subset of morphologically distinctmammary fat pads of rats treated with carcinogen, regardless of
whether the injected epithelial cells were treated with carcinogen myoepithelial cells, suggesting that myoepithelial cells may also
be subject to pathological alterations (Zhang et al., 2003). More-in vitro, also emphasizes the importance of stromal alterations
in the initiating steps of breast cancer (Maffini et al., 2004). over, in support of a role for myoepithelial cells in breast tumor
progression, it was recently reported that DCIS tumor epithelialNumerous in vitro and in vivo studies using diverse experimental
systems have demonstrated that the growth, survival, polarity, cells adjacent to a disrupted myoepithelial cell layer are molecu-
larly and genetically different from their more distant counter-and invasive behavior of breast cancer cells can be modulated
by myoepithelial and various stromal cells, and several genes parts (Man et al., 2003).
Myofibroblasts are stromal fibroblasts with features of bothhave been implicated to play an important role in this process
(Bissell et al., 2002; Coussens and Werb, 2002; Deugnier et al., myoblasts (e.g., expression of smooth muscle actin) and fibro-
blasts that have been implicated in breast cancer invasion, ex-2002; Elenbaas and Weinberg, 2001; Gudjonsson et al., 2002;
Kenny and Bissell, 2003; Radisky et al., 2001; Shekhar et al., tracellular matrix remodeling, wound healing, and chronic in-
flammation (De Wever and Mareel, 2003; Gabbiani, 1999;2003; Sternlicht and Barsky, 1997; Tlsty, 2001; Tlsty and Hein,
2001; Wiseman and Werb, 2002). However, comprehensive mo- Schurch, 1999). The cell type of origin of myofibroblasts is not
conclusively established. Certain cytokines can induce (TGF-)lecular analysis of all cell types that compose normal human
mammary breast tissue and breast carcinomas has not been or inhibit (IFN-) the transformation of fibroblasts into myo-
fibroblasts in vitro (De Wever and Mareel, 2003; Tanaka et al.,performed.
With the aim of delineating epithelial-stromal/myoepithelial 2003), while PDGF-B stimulates the proliferation of fibrocytes
and their conversion into myofibroblasts in vivo (Oh et al., 1998).cell interactions at the molecular level, we determined the com-
prehensive gene expression and genomic profiles of epithelial, Isolation of various stromal and epithelial cells from breast tu-
mors and their coculturing in vitro demonstrated that cancermyoepithelial, and stromal cells in normal breast tissue and in
situ and invasive breast carcinomas. Our results confirm at the epithelial cells can induce the expression of myofibroblast mark-
ers in a subset of fibroblasts (Ronnov-Jessen et al., 1995). How-molecular level that the cellular microenvironment is dramati-
cally different between normal breast tissue and breast carcino- ever, the finding that only a small fraction of fibroblasts were
transformed into myofibroblasts (Ronnov-Jessen et al., 1995)mas and that this is already evident at the in situ carcinoma
stage. Based on our gene expression data, we determined that raises the question of whether myofibroblasts could be derived
from specific stem cells that are normally present in the breastthe most dramatic and consistent changes occur in myoepithe-
lial cells and myofibroblasts and the majority of the differentially or in the bone marrow and are growth stimulated or recruited
by adjacent cancer epithelial cells. Recent data both in animalexpressed genes encode secreted and cell surface proteins
(Tables 1 and 2 and Supplemental Tables S2 and S5). Since models and human breast tumors support the hypothesis that
at least a subset of cancer-associated myofibroblasts is derivedprevious data also implicated these two cell types in breast
tumor progression, particularly in the transition of in situ to from circulating bone-marrow derived cells (Chauhan et al.,
2003; Ishii et al., 2003). Our finding that the gene expressioninvasive carcinomas (Alpaugh et al., 2000; Barsky, 2003; Chau-
han et al., 2003; Nguyen et al., 2000; Shao et al., 1998; Sternlicht profiles of myofibroblasts isolated from different invasive breast
carcinomas are highly similar also suggest their common celland Barsky, 1997; Sternlicht et al., 1997; Walter-Yohrling et
al., 2003), we mainly focused on tumor myoepithelial cells and type of origin.
Two genes highly expressed in tumor myoepithelial cellsmyofibroblasts and the genes expressed by them.
Myoepithelial cells play a major role in the formation of the and myofibroblasts encoding chemokines CXCL12 and CXCL14
were particularly interesting due to the recently demonstratedbasement membrane and lactation due to their expression of
type IV collagen, laminin, smooth muscle actin, and oxytocin role of chemokines and chemokine receptors in cancer cell
growth, invasion, and metastasis (Barbero et al., 2002; Chen etreceptor (Gudjonsson et al., 2002; Murrell, 1995). They also
have been suggested to suppress breast cancer cell growth, al., 2003; Hall and Korach, 2003; Kang et al., 2003; Muller et
al., 2001; Scotton et al., 2002). CXCL12 has been previouslyinvasion, and angiogenesis via shedding of CD44 and expres-
sion of protease inhibitors (Alpaugh et al., 2000; Barsky, 2003; implicated in breast cancer metastasis (Kang et al., 2003; Muller
et al., 2001), but its high expression in DCIS (a pre-invasiveXiao et al., 1999). On the other hand, myoepithelial cells are
also important for the survival, differentiation, and polarity of tumor) myofibroblasts suggests that it might have additional
roles in the earlier stages of breast tumorigenesis. Correlatingnormal luminal epithelial cells (Gomm et al., 1997a, 1997b).
Proteomic and mRNA expression profiling of short-term cul- with this hypothesis, CXCL12 was recently identified as a tran-
scriptional target of the estrogen receptor that mediates estro-tured myoepithelial cells and myoepithelial cell lines, respec-
tively, gave a glimpse of the molecular basis for the tumor and gen-induced proliferation of breast cancer cells (Hall and Kor-
ach, 2003). Relatively little is known about the CXCL14invasion suppressor role of normal myoepithelium (Barsky,
2003; Page et al., 1999). Our SAGE-based profiling of freshly chemokine despite the fact that it was independently identified
CANCER CELL : JULY 2004 27
A R T I C L E
by multiple labs using different approaches. The high expression could be due to the use of different technologies and ap-
of CXCL14 in inflammatory cells in multiple cancer types and proaches. All the studies that described LOH in cancer stroma
its selectivity to monoctyes may suggest a role in macrophage analyzed a few polymorphic markers and a fairly small popula-
development (Frederick et al., 2000; Hromas et al., 1999; Kurth tion of stromal cells isolated by microdissection from the same
et al., 2001; Sleeman et al., 2000). Although the receptor for area adjacent to tumor epithelial cells, while we analyzed all the
CXCL14 has not been identified, the induction of calcium mobili- stromal cells from the tumor and used comprehensive genome-
zation by recombinant CXCL14 in monocytes suggests that wide SNP arrays. Thus, if the stromal cells are highly heteroge-
similar to other chemokines, it is also likely to signal via a G neous with respect to genetic alterations, these changes can
protein-coupled receptor. Our preliminary results demonstrating be detected only if relatively few cells from the same area of
intracellular calcium flux in MDA-MB-231 breast cancer cells the tumor are analyzed. However, in our view this argues against
also support this hypothesis. the hypothesis that the genetic changes in the stroma are se-
In addition to phenotypic alterations, several recent studies lected for and thus play a major role in tumorigenesis.
described genetic changes (including LOH and mutations in In summary, this study provides a comprehensive molecular
tumor suppressor genes) in stromal cells adjacent to breast characterization of each cell type composing normal breast
cancer cells (Kurose et al., 2001, 2002; Lakhani et al., 1998; tissue and in situ and invasive breast carcinomas. The genes
Moinfar et al., 2000; Wernert et al., 2001). Loss of heterozygosity described here should therefore provide a valuable resource for
at several loci has also been demonstrated in normal-appearing future basic and clinical studies addressing the role of epithelial-
epithelial cells adjacent to breast carcinomas and short-term stromal cell interactions in breast and other cancer types. The
cultured luminal and myoepithelial cells (Deng et al., 1996; Forsti availability of specific chemokine receptor inhibitors and preclin-
et al., 2001; Lakhani et al., 1999; Moinfar et al., 2000). In several ical studies demonstrating dramatic tumor and metastasis sup-
cases, the tumor epithelial and stromal cells had discordant pressive effects using CXCR4 inhibitors in brain and breast
genetic changes, suggesting a clonal co-evolution for these two tumors (Rubin et al., 2003; Tamamura et al., 2003) provide a
cell types. Moreover, due to the low probability of two adjacent proof of principle that therapeutic targeting of chemokines is a
cells simultaneously acquiring genetic changes, this would also promising new opportunity for the treatment of breast carci-
suggest that breast cancer epithelial and stromal cells may be nomas.
derived from a common stem cell and then undergo a divergent
Experimental proceduresgenetic selection process.
In order to determine if in the same population of tumor
Cell lines and tissue specimensepithelial, myoepithelial, and stromal cells in which we detected
Breast cancer cell lines were obtained from American Type Culture Collectiondramatic gene expression changes there are also underlying
(Manassas, VA) or were generously provided by Drs. Steve Ethier (University
genetic alterations, we analyzed the genotype of these cell types of Michigan) and Arthur Pardee (Dana-Farber Cancer Institute). Cells were
using different technologies in 2 DCIS and 12 invasive breast grown in media recommended by the provider. Tumor specimens were
carcinomas. All but one of the tumor epithelial cells had numer- obtained from Brigham and Women’s and Massachusetts General Hospitals
(Boston, MA), Duke University (Durham, NC), University Hospital Zagrebous LOH involving almost all chromosome arms. The most fre-
(Zagreb, Croatia), and the National Disease Research Interchange, snapquent genetic changes we identified in the tumor epithelial cells
frozen on dry ice, and stored at 80	C until use or were processed for(1q, 8q, 17q, and 20q gain, and 6q, 8p, 10q, 12q, and 17p LOH),
purification as described below. All human tissue was collected using proto-both in DCIS and invasive tumors, were in agreement with that
cols approved by the Institutional Review Boards. We purified all the cell
of prior studies (Nishizaki et al., 1997; Waldman et al., 2000). types from 2 different normal reduction mammoplasty tissues, 2 different
The one tumor DNA sample (IDC10) that appeared to be devoid DCIS, and 13 different invasive ductal carcinomas. Due to technical difficul-
of significant LOH was obtained from a low-grade estrogen and ties (insufficient number of cells), we were not able to generate SAGE libraries
from each cell type of each tissue used for purification. In addition, selectedprogesterone receptor-positive, HER2-negative breast tumor.
cell types were isolated from a few additional normal and DCIS samples.The lack of gross chromosomal changes in this tumor is unlikely
The detailed protocol used for the purification of all cell types is includedto be due to technical issues, but potentially reflects a special
in the Supplemental Data. The estimated number of cells obtained frompathway of breast tumorigenesis. Correlating with this, an inde-
each fraction varied from 10,000 to 100,000.
pendent study using BAC array CGH analysis of a large set of
breast tumors also found that a subset of breast tumors (9/146) Generation and analysis of SAGE libraries, mRNA in situ
have minimal (1.5% of the genome) chromosomal changes hybridization, and immunohistochemistry
All SAGE libraries were generated using a modified micro-SAGE protocol(Dr. J. Gray, Lawrence Berkeley National Laboratory, personal
and the I-SAGE (libraries prepared in 2002) or long I-SAGE (I-epi-7, I-epi-8,communication). Using three different methods (aCGH, SNP
I-epi-9, I-leu-7, I-str-7, I-myofib-7, I-myofib-8, I-myofib-9, D-str-6, FA, PHY)arrays, and direct sequencing of specific SNPs), we detected
kits from Invitrogen. The samples were collected and SAGE libraries weregenetic changes only in cancer epithelial cells. However, in a
generated during 2002–2004, and the long-SAGE kit became available only
malignant phyllodes tumor that is thought to be composed of in 2003. SAGE libraries were sequenced by Agencourt (Beverly, MA) as
malignant stroma and epithelium, we detected LOH in both part of the NCI-CGAP SAGE project, and all data will be deposited to the
components. These results suggest that using the technologies SAGEGenie website (http://cgap.nci.nih.gov/SAGE). Approximately 50,000
tags (average tag number 56,647 
 4,383) were obtained from each library,we applied, genetic changes can be detected both in epithelial
and the preliminary analysis of the SAGE data was performed essentiallyand stromal cells, but only if there is a mono- or oligoclonal
as described (Porter et al., 2001). Briefly, genes significantly (p  0.002)proliferation of neoplastic epithelial or stromal cells. Our inability
differentially expressed between normal and cancerous cells were identified
to find conclusive genetic alterations in stromal cells from inva- by performing pair-wise comparisons using the SAGE2000 software and
sive ductal breast carcinomas is seemingly in disagreement Monte Carlo analysis. Significance calculation among groups of SAGE librar-
with the findings of several of the above referenced studies. ies and clustering analyses were performed using a new Poisson model-
based K-means algorithm (PK algorithm, Cai et al., 2004). A detailed descrip-However, we believe that the reason for the different results
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tion of the methodology used for the analysis and clustering of the SAGE TN). We transfected mammalian cells with Fugene6 (Roche, Indianapolis,
data is provided in the Supplemental Data. Probes for the selected genes IN), Lipofectamine, or Lipofectamine 2000 (LifeTechnologies, Rockville, MD)
to be used for mRNA in situ hybridization were generated by PCR amplifica- reagents. We performed in vivo and in vitro ligand binding assays on primary
tion of a 300–500 bp region of the 3UTR and subcloning the fragments into tissues and cell lines using AP-CXCL14 essentially as described (Flanagan
pZERO1.0 (Invitrogen). The identity of the subcloned PCR products was and Leder, 1990; Porter et al., 2003b). Briefly, we fixed frozen sections of
confirmed by sequencing, and the resulting plasmids were used for the various human specimens, incubated with either AP-CXCL14 fusion protein
generation of digitonin-labeled riboprobes essentially as described (Porter or AP control conditioned medium, rinsed, and then incubated with AP
et al., 2003a). mRNA in situ hybridizations and immunohistochemistry were substrate forming a blue/purple precipitate. For in vitro assays we incubated
performed as described or as recommended by the antibody supplier (Porter cells in suspension with conditioned media containing either AP alone or
et al., 2003a). Mouse monoclonal antibodies for IL1 and CCL3 were pur- AP-CXCL14 fusion protein, rinsed, and then assayed for bound AP activity.
chased from R&D, while anti-CD45 and anti-Ki67 mouse monoclonal anti- To determine the effect of CXCL14 on cell growth, we plated MDA-MB-231
bodies were obtained from DAKO. and MCF10A cells (4000 cells/well in a 24-well plate) and grew them in
conditioned media containing AP or AP-CXCL14. Conditioned media were
Array comparative genomic hybridization generated by transfecting 293 cells with pAP-tag5 or pAP-CXCL14 plasmids
cDNA array comparative genomic hybridization using Agilent (Palo Alto, and growing them in McCoy’s medium supplemented with 10% FBS (to be
California) arrays were performed by the Belfer Genome Center at the Dana- used for MDA-MB-231 cells) or in MCF10A media (American Type Culture
Farber Cancer Institute. Genomic DNA was digested with DpnII and random Collection, Manassas, VA, to be used in MCF10A cells). Cells were counted
prime labeled according to standard protocols with slight modifications (3 wells/time point) on days 1, 2, 4, 6, and 8 after plating. We used 10 nM
(Pollack et al., 1999). (For a detailed protocol, see http://genomic.dfci.harvard. CXCL12 in MDA-MB-231 cells as positive control. The experiment was
edu/array_cgh.htm.) Labeled DNAs were hybridized to human cDNA mi- repeated three times. In order to determine if CXCL14 binding to breast
croarrays containing 12,814 unique cDNA clones (Agilent Technologies, Hu- cancer cells has an effect on cell migration and invasion, we tested the ability
man 1 clone set). Among these clones, approximately 9,420 unique map of conditioned medium containing AP-CXCL14 or pCDNA3.1 expressing HA-
positions were found for 12,020 unique GenBank sequences. The median tagged CXCL14 to induce the migration and invasion of MDA-MB-231 cells
interval between cDNAs is 100.1 kilobase, 92.8% of intervals are less than using BIOCOAT Matrigel invasion chambers essentially as described (Muller
1 megabase, and 98.6% are less than 3 megabases. The density of coverage et al., 2001). For invasion assays, we plated 2.5 104 cells/well and assayed
is closely correlated with gene density. Following extensive QA analysis, 24 hr later, while for migration assays we used 1.25  104 cells/well and
fluorescence ratios of scanned images of the arrays were calculated and determined cell numbers 12 hr later. Conditioned medium of cells transfected
the raw array CGH profiles were processed to identify statistically significant with pAP-Tag5 or pCDNA 3.1 empty vectors were used as negative control.
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